Clinical and pharmacokinetic studies indicate that optimizing 5-HTP administration requires careful, gradual dose escalation to manage bioavailability and minimize adverse gastrointestinal side effects.
Paper [1] provides direct pharmacokinetic evidence regarding steady-state bioavailability, linear pharmacokinetics, and the clinical importance of slow initiation to prevent nausea and vomiting for orally administered L-5-HTP. Paper [6] reviews 5-hydroxytryptophan within the context of tryptophan metabolism and therapeutic protocols for mood disorders. None of the retrieved papers refute the claim, making the verdict SUPPORTED.